Challenges and advances in nanoparticle-based oral insulin delivery

Expert Review of Medical Devices

Volumn 6, Issue 6, 2009, Pages 665-676

  Ramesan, Rekha M ^a   Sharma, Chandra P ^a  

^a SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

Author keywords

Bioavailability; Biocompatibility; Diabetes; Intestinal uptake; Nanoparticle; Oral insulin

Indexed keywords

ALGINIC ACID; CALCIUM PHOSPHATE; CHITOSAN; COPOLYMER; CYANOACRYLATE DERIVATIVE; ELIGEN; IN 105; INSULIN; MACROGOL; NANOCARRIER; ORA LYN; POLY(FUMARIC CO SEBACIC ANHYDRIDE); POLYALKYLCYANOACRYLATE; POLYCAPROLACTONE; POLYGLACTIN; POLYMETHACRYLIC ACID; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG;

BIOCOMPATIBILITY; BIODEGRADABILITY; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; DRUG UPTAKE; ENDOCYTOSIS; ENZYME INHIBITION; GASTROINTESTINAL TRACT; HUMAN; INTESTINE ABSORPTION; MUCOADHESION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PATIENT COMPLIANCE; PHYSICAL CHEMISTRY; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SYSTEMIC CIRCULATION;

ADMINISTRATION, ORAL; ANIMALS; BIOCOMPATIBLE MATERIALS; CELL LINE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EQUIPMENT AND SUPPLIES; HUMANS; INSULIN; NANOPARTICLES; NANOTECHNOLOGY; POLYMERS; TECHNOLOGY, PHARMACEUTICAL;

EID: 73549111762     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.09.43     Document Type: Review

References (87)

1. Banting FG, Best CH, Collip JB et al. Pancreatic extractions in the treatment of diabetes mellitus: preliminary report. Can. Med. Assoc. J. 12, 141-146 (1922).
2. Wild S, Roglic G, Green A et al. Global prevalence of diabetes. Diabetes Care 27(5), 1047-1053 (2004).
3. International Diabetes Federation. Diabetes Atlas. International Diabetes Federation, Brussels, Belgium (2007).
4. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 358, 739-746 (2001).
5. Henry RR, Gumbiner B, Ditzler T et al. Intensive conventional insulin therapy for Type II diabetes: metabolic effects during a 6-month outpatient trial. Diabetes Care 16, 21-31 (1993).
6. Feskens EJ, Kromhout D. Hyperinsulinemia, risk factors, and coronary heart disease. The Zutphen Elderly Study. Arterioscler. Thromb. 14, 1641-1647 (1994).
7. Still JG. Development of oral insulin: progress and current status. Diabetes Metab. Res. Rev. 18(Suppl. 1), S29-S37 (2002).
8. Khafagy E-S, Morishita M, Onuki Y et al. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv. Drug Deliv. Rev. 59, 1521-1546 (2007). Informative and interesting review on noninvasive routes of insulin administration and the current approaches.
9. Damge C, Pinto C, Maincent P. Nanoparticle strategies for the oral delivery of insulin. Expert Opin. Drug Deliv. 5(1), 45-68 (2008). Thorough review on nanoparticle-based oral insulin delivery covering every aspect from the nanoparticle preparation and stability to uptake and bioavailability of various formulations.
10. Babu VR, Patel P, Mundargi RC et al. Developments in polymeric devices for oral insulin delivery. Expert Opin. Drug Deliv. 5(4), 403-415 (2008). Covers the developments in the advances of polymeric systems developed for oral delivery of insulin.
11. Woitiski CB, Carvalho RA, Ribiero AJ et al. Strategies toward the improved oral delivery of insulin nanoparticles via gastrointestinal uptake and translocation. BioDrugs 22(4), 223-237 (2008).
12. Pickup JC, Zhi Z-L, Khan F. Nanomedicine and its potential in diabetes research and practice. Diabetes Metab. Res. Rev. 24(8), 604-610 (2008).
13. Alonso MJ. Nanomedicines for overcoming biological barriers. Biomed. Pharmacother. 58(3), 168-172 (2004).
14. Chalasani KB, Russell-Jones G-J, Yandrapu SK et al. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J. Control. Release 117(3), 421-429 (2007).
15. Chalasani KB, Russell-Jones G-J, Jain AK et al. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J. Control. Release 122(2), 141-150 (2007).
16. Kavimandan NJ, Losi E, Peppas NA. Novel delivery system based on complexation hydrogels as delivery vehicles for insulin-transferrin conjugates. Biomaterials 27(20), 3846-3854 (2006).
17. Kim BY, Jeong JH, Park K. Bioadhesive interaction and hypoglycemic effect of insulin-loaded lectin-microparticle conjugates in oral insulin delivery system. J. Control. Release 102, 525-538 (2005).
18. Pappenheimer JR. Physiological regulation of transepithelial impedance in the intestinal mucosa of rats and hamsters. J. Memb. Biol. 100(1), 137-148 (1985).
19. Madara JL. Regulation of the movement of solutes across tight junctions. Annu. Rev. Physiol. 60, 143-159 (1998).
20. Anderson JM, Van Itallie CM. Tight junctions and the molecular basis for regulation of paracellular permeability. Am. J. Physiol. 269, G467-G475 (1995).
21. Nusrat A, Turner JR, Madara JL. Molecular physiology and pathophysiology of tight junctions: IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am. J. Physiol.: Gasterointest. Liver Physiol. 279(5), G851-G857 (2000).
22. Fromter E, Diamond J. Route of passive ion permeation in epithelia. Nat. New Biol. 53, 9-13 (1972).
23. Damge C, Michel C, Aprahamian M et al. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 37(2), 246-251 (1988).
24. Cournarie F, Auchere D, Chevenne D et al. Absorption and efficiency of insulin after oral administration of insulin-loaded nanocapsules in diabetic rats. Int. J. Pharm. 242(1), 325-328 (2002).
25. Foss AC, Goto T, Morishits M et al. Development of acrylic-based copolymers for oral insulin delivery. Eur. J. Pharm. Biopharm. 6(9-10), 163-169 (2004).
26. Simon M, Behrens I, Dailey LA et al. Nanosized insulin-complexes based on biodegradable amine-modified graft polyesters poly-graft-poly- (l-lactic acid): protection against enzymatic degradation, interaction with Caco-2 cell monolayers, peptide transport and cytotoxicity. Eur. J. Pharm. Biopharm. 66, 165-172 (2007).
27. Xiong XY, Li YP, Li ZL et al. Vesicles from pluronic/poly (lactic acid) block copolymers as new cariers for oral insulin delivery. J. Control. Release 120(1-2), 11-17 (2007).
28. Sajeesh S, Sharma CP. Novel pH responsive polymethacrylic acid-chitosanpolyethylene glycol nanoparticles for oral peptide delivery. J. Biomed. Mat. Res. 76B(2), 298-305 (2006).
29. Rekha MR, Sharma CP. Phthalyl chitosan-poly(ethylene oxide) semiinterpenetrating polymer network microparticles for oral protein delivery: an in vitro characterization. J. Appl. Polym. Sci. Symp. 110(5), 2787-2795 (2008).
30. Ramachandran R, Paul W, Sharma CP. Synthesis and characterization of PEGylated calcium phosphate nanoparticles for oral insulin delivery. J. Biomed. Mater. Res. B Appl. Biomater. 88(1), 41-48 (2009).
31. Nakamura K, Morishita M, Ehara J. Key functions in polymer carriers for intestinal absorption of insulin. Int. J. Pharm. 354, 135-142 (2008).
32. Damge C, Vranckx H, Balschmidt P et al. Poly(alkylcyanoacrylate) nanospheres for oral administration of insulin. J. Pharm. Sci. 86, 1403-1409 (1997).
33. Damge C, Aprahamian M, Humbert W et al. Ileal uptake of poly(alkylcyanoacrylate) nanocapsules in the rat. J. Pharm. Pharmacol. 52, 1049-1056 (2000).
34. Meisha MS, Sidhom MB, Fasipe B. Oral and subcutaneous absorption of insulin poly (alkylcyanoacrylate) nanoparticles. Int. J. Pharm. 288, 289-293 (2005).
35. Aboubakar M, Puisieux F, Couvreur P et al. Study of the mechanism of insulin encapsulation in poly (alkylcyanoacrylate) nanocapsules obtained by interfacial polymerisation. J. Biomed. Mat. Res. 47, 568-576 (1999).
36. Watnasirichaikul S, Davies NM, Rades T. In vitro release and oral bioactivity of insulin in diabetic rats using nanocapsules dispersed in biocompatible microemulsion. J. Pharm. Pharmacol. 54, 473-480 (2002).
37. Aboubakar M, Puisieux F, Couvreur P. Physico-chemical characterization of insulin-loaded poly(isobutylcyanoacrylate) nanocapsules obtained by interfacial polymerization. Int. J. Pharm. 183, 63-66 (1999).
38. Damge C, Maincent P, Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J. Control. Release 117(2), 271-280 (2007).
39. Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J. Biomater. Sci. Polymer 17(3), 247-289 (2006).
40. Mundargi RC, Babu VR, Rangaswamy V et al. Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. J. Control. Release 125(3), 193-209 (2008).
41. Davaran S, Omidi Y, Rashidi MR et al. Preparation and in vitro evaluation of linear and star-branched PLGA nanoparticles for insulin delivery. J. Bioactive Comp. Pol. 23(2), 115-131 (2008).
42. Carino GP, Jacob JS, Mathiowitz E. Nanosphere based oral insulin delivery. J. Control. Release 65(1-2), 261-269 (2000).
43. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm. Res. 15, 1326-1331 (1998).
44. Pan Y, Li Y-J, Zhao H-Y. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int. J. Pharm. 249 139-147 (2002).
45. Cui F, Zhang L, Zheng J, Kawashima Y. A study of insulin-chitosan complex nanoparticles used for oral administration. STP Pharma. 14(6), 435-439 (2004).
46. Sarmento B, Ribeiro A, Veiga F. Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromolecules 8(10), 3054-3060 (2007).
47. Rekha MR, Sharma CP. Synthesis and evaluation of lauryl succinyl chitosan particles towards oral insulin delivery and absorption J. Control. Release 135(2), 144-151 (2009).
48. Lin HS, Chen C-T, Liang H-F et al. Novel nanoparticles for oral insulin delivery via the paracellular pathway. Nanotechnology 18, 105102 (2007).
49. Reis CP, Veiga FJ, Ribeiro AJ et al. Nanoparticulate biopolymers deliver insulin orally eliciting pharmacological response. J. Pharm. Sci. 97, 5290-5305 (2008).
50. Sarmento B, Ferreira DC, Jorgensen L. Probing insulin's secondary structure after entrapment into alginate/chitosan nanoparticles. Eur. J. Pharm. Biopharm. 65(1), 10-17 (2007).
51. Hovgaard L, Mack EJ, Kim SW. Insulin stabilization and GI absorption. J. Control. Release 19, 99-108 (1992).
52. Sajeesh S, Sharma CP. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int. J. Pharm. 325(1-2), 147-154 (2006).
53. Yamamoto A, Taniguchi T, Rikyuu K et al. Effect of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm. Res. 11 1496-1500 (1994).
54. Liu H, Tang R, Pan WS et al. Potential utility of various protease inhibitors for improving the intestinal absorption of insulin in rats. J. Pharm. Pharmacol. 55, 1523-1529 (2003).
55. Kakade ML, Hoffa DE, Liener IE. Contribution of trypsin inhibitors to the deleterious effects of unheated soybeans fed to rats. J. Nutr. 103, 1772-1778 (1973).
56. Lueßen HL, Bochard G, Verhoef JC et al. Mucoadhesive polymers in peroral peptide drug delivery. II. Carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. Pharm. Res. 12, 1293-1298 (1995).
57. Lueßen HL, de Leeuw BJ, Pérard D et al. Mucoadhesive excipients in peroral peptide drug delivery. I. Influence of mucoadhesive excipients on the proteolytic activity of intestinal enzymes. Eur. J. Pharm. Sci. 4, 117-128 (1996).
58. Jintapattanakita A, Junyapraserta VB, Maob S et al. Peroral delivery of insulin using chitosan derivatives: a comparative study of polyelectrolyte nanocomplexes and nanoparticles. Int. J. Pharm. 342(1-2), 240-249 (2007).
59. Malkov D, Angelo R, Wang H et al. Oral delivery of insulin with the Eligen® technology: mechanistic studies. Curr. Drug Deliv. 2, 191-197 (2005).
60. Mikos AG, Peppas NA. Systems for controlled release of drugs. V. Bioadhesive systems. STP Pharma 2, 705-716 (1986).
61. Peppas NA, Buri P. Interfacial and molecular aspects of bioadhesion on soft tissues. J. Control. Release 2, 257-275 (1985).
62. Lehr CM, Bouwstra JA, de Boer AG et al. Intestinal Bioadhesive Drug Delivery System, Drug Targeting and Delivery Concepts in Dosage from Design. Junginger HE (Ed.). Ellis Horwoord, Chichester, England, UK, 93-110 (1992).
63. Bernkop-Schnürch A, Kast CE, Richter MF. Improvement in the mucoadhesive properties of alginate by the covalent attachment of cysteine. J. Control. Release 71, 277-285 (2001).
64. Morishita M, Goto T, Peppas NA et al. Mucosal insulin delivery systems based on complexation polymer hydrogels: effect of particle size on insulin enteral absorption. J. Control. Release 97, 115-124 (2004).
65. Pinto-Alphandary H, Aboubakar M, Jaillard D et al. Visualization of insulinloaded nanocapsules: in vitro and in vivo studies after oral administration to rats. Pharm. Res. 20(7) 1071-1084 (2003).
66. Aboubakar M, Couvreur P, Pinto-Alphandary H et al. Insulin-loaded nanocapsules for oral administration: in vitro and in vivo investigation. Drug Dev. Res. 49, 109-117 (2000).
67. Ma Z, Lim TM, Lim L-Y. Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats. Int. J. Pharm. 293, 271-280 (2005).
68. Bailey CA, Bryla P, Malick AW. The use of the intestinal epithelial cell culture model, Caco-2, in pharmaceutical development. Adv. Drug Del. Rev. 22(1-2), 85-103 (1996).
69. Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96(3), 736-749 (1989).
70. Angela PA, Reddy MB. Caco-2 cells can be used to assess human iron bioavailability from a semipurified meal. J. Nutrition 130, 1329-1334 (2000).
71. Pinto M, Robine-Leon S, Appay M-D et al. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol. Cell 47, 323-330 (1983).
72. Behrens I, Isabel A, Pena V et al. Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm. Res. 20(7), 1185-1193 (2003).
73. des Rieux A, Ragnarsson EGE, Gullberg E et al. Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur. J. Pharm. Sci. 25, 455-465 (2005).
74. Sadeghi AMM, Dorkoosh FA, Avadi MR. Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. Eur. J. Pharm. Biopharm. 70, 270-278 (2008).
75. Carino GP, Jacob JS, Mathiowitz E. Nanosphere based oral insulin delivery. J. Control. Release 65, 261-269 (2000).
76. Cui F, Shi K, Zhang L et al. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J. Control. Release 114(2), 242-250 (2006).
77. Sonaje K , Lin Y-H, Juang J-H. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 30, 2329-2339 (2009).
78. Cui F, Tao A-J, Cun D-M et al. Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery. J. Pharm. Sci. 96(2), 421-427 (2006).
79. Williams F, Saffran M. Insulin in the drinking water of rats. Drug Delivery 3(2), 81-85 (1996).
80. Blunk T, Hochstrasser DF, Sanchez J-C et al. Colloidal carriers for intravenous targeting: plasma protein adsorption patterns on surfacemodified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 14, 1382-1387 (1993).
81. Luck M, Paulke B-R, Schro der W et al. Analysis of plasma protein adsorption on polymeric nanoparticles with different surface chacteristics. J. Biomed. Mater. Res. 39, 478-485 (1998).
82. Ovens DE III, Peppas NA. Opsonisation, biodistribution and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307, 93-102 (2006).
83. Hall JB, Dobrovolskaia MA, Patri AK. Characterisation of nanoparticles for therapeutics. Nanomedicine 2(6), 789-803 (2007).
84. Jacobson-Kram D, McGovern T. Toxicological overview of impurities in pharmaceutical products. Adv. Drug Deliv. Rev. 59, 38-42 (2007).
85. Reis CP, Figueiredo IV, Carvalho RA. Toxicological assessment of orally delivered nanoparticulate insulin. Nanotoxicology 2(4), 205-217 (2008)
86. Mathieu C, Gale EAM. Inhaled insulin: gone with the wind? Diabetologia 51, 1-5 (2008).
87. WHO, 2000 and 2030 Diabetes World Figures (2009) www.who.int/diabetes/ facts/world-figures/en/